Floatz logo

bnt323

HER2-positive Advanced Solid Tumor

DualityBio Inc.Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the HER2-positive Advanced Solid Tumor cohort.

Asset / SponsorPhaseRating
RITONAVIR
DualityBio Inc.
Phase 1/2CCC
Trastuzumab Pamirtecan
DualityBio Inc.
Phase 1/2CCC
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
DualityBio Inc.
Phase 1/2CCC
Itraconazole
DualityBio Inc.
Phase 1/2CCC
zv0203
Hangzhou Adcoris Biopharmacy Co., Ltd
Phase 1CC

Same molecule, other indications

bnt323 is also rated in:

breast cancerDormant
BB
Indicative ·
64 / 100
View asset →
HER2 positive breast carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
breast carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →